The new generation of anti-diabetic drugs GLP-1 receptor agonists (GLP-1RAs) have shown promising benefits on T2D treatment, as well as the DPP-4 inhibitors, which raises levels of GLP-1 and GIP to augment insulin release after a meal. Here, GCG is linked to type 2 diabetes mellitus.